Clinical Trials Logo

Virus clinical trials

View clinical trials related to Virus.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04636294 Completed - Covid19 Clinical Trials

Borderline COVID-19 PCR Test Result

Start date: August 1, 2020
Phase:
Study type: Observational

Follow-up of patients with a borderline PCR result. Data of patients that were re-tested within 96 hours after receiving a borderline COVID-19 PCR result are reviewed. This is a retrospective study.

NCT ID: NCT03463694 Completed - Pediatric ALL Clinical Trials

Edinburgh and Lothian Virus Intervention Study in Kids

ELVIS Kids
Start date: November 2, 2018
Phase: N/A
Study type: Interventional

ELVIS Kids is a parallel, open label, randomised controlled trial (RCT) of Hypertonic Saline (HS) nose drops (~2.6% NaCl) vs. standard care in children <7 years of age with symptoms of an Upper Respiratory Tract Infection (URTI).

NCT ID: NCT02743663 Completed - Asthma Clinical Trials

The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children

WheezyER
Start date: June 2014
Phase:
Study type: Observational

The study will ascertain the ability of preschool lung function tests to distinguish healthy children from those with wheeze, and to differentiate phenotypes of wheezy children (high and low risk for asthma as defined by API) in order to predict response to therapy, and to explore the correlation between preschool lung function test results and symptoms, in order to develop objective methods for monitoring asthma.

NCT ID: NCT01159561 Completed - Virus Clinical Trials

Western Equine Encephalitis Vaccine, Inactivated

WEE
Start date: February 2010
Phase: Phase 1
Study type: Interventional

This study is designed to determine the safety and immunogenicity of WEE Vaccine Lot number 3-1-92.

NCT ID: NCT01136395 Completed - Clinical trials for Kidney Transplantation

Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation

Start date: January 2010
Phase: Phase 2
Study type: Interventional

This project comprises immunological and virological analyses within a prospective clinical study of Rituximab (Rtx)-treated blood group incompatible living donor (LD) renal transplant recipients compared to blood group compatible LD recipients without Rtx induction, and of living donor compared to deceased donor renal transplant recipients treated with tacrolimus (Tacr)/mycophenolate sodium (MPS). Aim of this project is to assess short- and long-term effects of immunosuppressive therapy (Rtx induction) and of living donation on immunological and histological parameters of graft outcome and on viral replication (BK virus (BKV), JC virus (JCV), cytomegalovirus (CMV), Epstein Barr virus (EBV)) with the potential to improve long-term graft outcome and to enable risk estimation of virus disease.